Browse grants
Federal opportunities with plain-English eligibility summaries. We aggregate public records — always verify the details on the funder’s site before applying.
NIH Research Education Program - Courses, Curriculum & Methods (Parent R25 - Clinical Trial Not Allowed)
Due May 25, 2029National Institutes of Health · Amount varies
The National Institutes of Health (NIH) Research Education Program supports research education activities in the mission areas of the NIH. The overarching goal of the Research Education program is to:Support educational activities that complement and/or enhance training of a workforce to meet the nation's biomedical, behavioral and clinical research needs;Help recruit individuals with specific specialty or disciplinary backgrounds to research careers in biomedical, behavioral and clinical sciences; andFoster a better understanding of biomedical, behavioral and clinical research and its implications.
Limited Competition: Centers of Biomedical Research Excellence: Expansion/Sustainability Phases (COBRE-E/S) (P30 - Clinical Trial Not Allowed)
Due May 25, 2029National Institutes of Health · Amount varies
The Institutional Development Award (IDeA) program supports biomedical research capacity building in states that have historically received low levels of NIH funding. The Centers of Biomedical Research Excellence: Expansion/Sustainability Phases (COBRE-E/S) Notice of Funding Opportunity (NOFO) supports the expansion and sustainability of biomedical research centers in IDeA-eligible institutions. These centers will focus on building research capacity in broad scientific areas of strategic importance for the institutions. The goal of COBRE-E is to expand research capacity by growing the institutional faculty base and supporting research projects and core facilities in the new area. The objective of COBRE-S is to sustain the infrastructure by continuing the growth of the faculty base and consolidating research cores. This is a Notice of Funding Opportunity (NOFO) for a Limited Competition that will invite application(s) from eligible organization(s) to apply. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered.
NIDCR Prospective Observational or Biomarker Validation Study Cooperative Agreement (U01 Clinical Trial Not Allowed)
Due Jul 5, 2029National Institutes of Health · Up to $500K
This Notice of Funding Opportunity (NOFO) will support, through the cooperative agreement mechanism, investigator-initiated observational studies or biomarker validation studies that require prospective collection of data/biospecimens or continued analysis of data/biospecimens.
Causal Hypotheses on the Oral-Systemic Health Impacts of Human Behaviors among People with Chronic Conditions (U01 Clinical Trial Not Allowed)
Due Jul 5, 2029National Institutes of Health · Up to $500K
This Notice of Funding Opportunity (NOFO) invites applications for innovative research on the factors that cause human behaviors and the oral-systemic health impacts of those behaviors to enhance health, lengthen life, and reduce illness and disability among people with chronic conditions. Causal hypotheses may include biological, biopsychosocial, congenital, environmental, interpersonal, neurological, psychological, and comorbidity factors that individually, sequentially, or in combination trigger human behaviors and oral-systemic health outcomes, with impacts that may be direct or traceably distal. Applications that propose projects to develop or refine causal hypotheses also are encouraged.
Research Opportunities in Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed)
Due Jul 5, 2029National Institutes of Health · Amount varies
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) encourages grant applications to support research in cancer epidemiology cohort studies that address specific knowledge gaps in cancer etiology and survivorship. Applications should include hypothesis-based research, support for cohort infrastructure and/or maintenance, continued follow-up, and sharing of data and biospecimen resources as appropriate.
Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)
Due Jul 5, 2029National Institutes of Health · Up to $500K
This Notice of Funding Opportunity (NOFO) encourages collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods, and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical, or translational science. This NOFO will support clinical trials that test functionality or validate performance in the chosen setting. This NOFO is not intended to support conventional clinical trials that lack translation as the primary motivation. Applications that propose phase III clinical trials in any area of research are not sought by and will not be supported through this NOFO. This NOFO does not support commercial production.
NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)
Due Jul 5, 2029National Institutes of Health · Amount varies
This notice of funding opportunity (NOFO) encourages applications for implementation of investigator-initiated, milestone driven clinical trials that need enhanced oversight, and as applicable, include mechanistic studies. Mechanistic work in clinical trials may be of great value because it promotes the understanding of human diseases and the development of future therapeutic modalities. Support is available for clinical trials up to 5 years, as well as for extended clinical trials of 6- or 7-years.Investigators are encouraged to visit this NIH website for additional information about the overall mission and research areas of NIAID.Only one clinical trial may be proposed in each NIAID Clinical Trial Implementation Cooperative Agreement (U01) application. In accordance with NIH standard peer-review processes, the applications will be peer-reviewed, and only meritorious applications will be considered.
Academic Career Excellence (ACE) Award (K32 Independent Clinical Trial Not Allowed)
Due Jul 12, 2029National Institutes of Health · Amount varies
The purpose of the Academic Career Excellence (ACE) Award (K32) is to support rigorous, mentored scientific research and career development for up to three years for early-stage postdoctoral scholars. Candidates must submit their application up to one year prior to beginning their postdoctoral position or no more than two years after their postdoctoral training begins (resubmissions included). The ACE K32 will foster early, goal-directed planning and encourage innovative applications with the potential for a significant impact on scientific research and career development. Inclusion of preliminary data are not required as the ACE K32 emphasizes innovative research ideas and thoughtful plans for training and mentorship that will facilitate the development of the postdoctoral scholars who have the potential to become productive, independent investigators in research fields relevant to the missions of the participating NIH Institutes and Centers.
Limited Competition: Small Grant Program for Mentored Research Career Development Award Recipients (R03) (Clinical Trials Not Allowed)
Due Jul 16, 2029National Institutes of Health · Amount varies
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) announces a program that provides NIAMS-supported K01, K08, K23, and K25 recipients the opportunity to apply for the Small Grant (R03) during the second to fourth year of their K award, as well as to provide support to recipients of significant career development awards from federal or non-federal organizations that are focused on the NIAMS' mission areas. Through this mechanism, which allows up to $50,000 direct costs per year for up to two years, the NIAMS is seeking to enhance the capability of scientists to conduct research as they transition to fully independent investigator. The R03 grant mechanism allows support of different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. In addition to the existing career development awards, the R03 is intended to support short term research projects to enable opportunities for a subsequent R01, or equivalent, application. Clinical trials of any phase will not be supported by this NOFO.This is a Notice of Funding Opportunity (NOFO) for a Limited Competition that will invite application(s) from eligible organization(s) to apply. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered for funding.
RFA-GH-18-000
Due Sep 30, 2030Centers for Disease Control and Prevention - ERA · $0
Submit application as necessary.
RFA-DD-18-000
Due Sep 30, 2030Centers for Disease Control and Prevention - ERA · $0
Submit application as necessary.
RFA-SH-18-000
Due Sep 30, 2030Centers for Disease Control and Prevention - ERA · $0
Submit application as necessary for Type 6 Applications.
RFA-PS-18-000
Due Sep 30, 2030Centers for Disease Control and Prevention - ERA · $0
Submit application as necessary for Type 6 Applications.
RFA-EH-18-000
Due Sep 30, 2030Centers for Disease Control and Prevention - ERA · $0
Submit application as necessary for Type 6 Applications.
RFA-DP-18-000
Due Sep 30, 2030Centers for Disease Control and Prevention - ERA · $0
Submit application as necessary for Type 6 Applications.
RFA-CK-18-000
Due Sep 30, 2030Centers for Disease Control and Prevention - ERA · $0
Submit application as necessary for Type 6 Applications.
RFA-TS-18-000
Due Sep 30, 2030Centers for Disease Control and Prevention - ERA · $0
Submit application as necessary for Type 6 Applications.
RFA-CE-18-000
Due Sep 30, 2030Centers for Disease Control and Prevention - ERA · $0
Submit application as necessary for Type 6 Applications.
RFA-OE-18-000
Due Sep 30, 2030Centers for Disease Control and Prevention - ERA · $0
Submit application as necessary for Type 6 Applications.
RFA-IP-18-000
Due Sep 30, 2030Centers for Disease Control and Prevention - ERA · $0
Submit application as necessary for Type 6 Applications.